Please login to the form below
Huntington's disease
This page shows the latest Huntington's disease news and features for those working in and with pharma, biotech and healthcare.
AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies
AbbVie has decided to exit its existing partnership with Voyager Therapeutics for the development of gene therapies for Alzheimer’s and Parkinson’s disease. ... This included handing back the rights to a number of candidates, including a potential
Latest news
-
Teva’s weak pipeline hit by Tourette’s drug trial failure
Deutetrabenazine is already approved as Austedo for the treatment of movement disorder chorea in patients with Huntington’s disease and for tardive dyskinesia – a side effect of antipsychotic drugs – but Teva ... 110 and Otsuka’s
-
Troubled Alkermes eyes November OK for new antipsychotic
The increased weight not only heightens patients’ risk of cardiovascular disease, but also reduces their quality of life and can lead to poor compliance with treatment. ... Huntington’s disease.
-
Wave’s challenge to Sarepta in Duchenne falls flat
The demise of Wave’s programmes leaves Japan’s Nippon Shinyaku Pharma as the main rival to Sarepta in DMD. ... Another drug candidate derived from that platform – WVE-120102 for Huntington’s disease – is in a phase 1b/2a trial (PRECISION-HD2)
-
Alkermes boosts CNS presence with $950m Rodin acquisition
The deal will see Alkermes expand its reach into central nervous system (CNS) diseases, by gaining a portfolio of pre-clinical assets for Alzheimer’s disease, Huntington’s disease, frontotemporal dementia ... Rodin's targeted approach to
-
Sanofi exiting Voyager gene therapy pact is ‘surprising’, says analyst
The $845m deal focused mainly on central nervous system diseases, and was formed in 2015 with a Parkinson’s disease candidate the lead project. ... Sanofi handed back rights to that two years ago, and has now done the same with gene therapies for
More from news
Approximately 6 fully matching, plus 41 partially matching documents found.
Latest Intelligence
-
Bluebird: on a mission to ‘recode’ the DNA of healthcare
to learn from its own mistakes with therapies for Huntington’s disease and also haemophilia. ... Increasingly factored into this equation is competition from companies following Bluebird into beta thalassemia and sickle cell disease.
-
Brain power: fresh approaches to Alzheimer’s drug discovery
Two further candidates, AL003 for Alzheimer’s disease and AL004 for multiple degenerative disorders, are also set to enter clinical trials this year. ... Diseases include Alzheimer’s, dementia with Lewy bodies, frontotemporal dementia, as well as
-
Deal Watch October 2018
Collaboration for. development. $760m. Enterome/. Takeda. EB8018 for Crohn’s disease and other gastrointestinal. ... Roche has an existing agreement with Ionis for IONIS‐HTTRx, an antisense drug for Huntington’s Disease, and the new deal is to
-
The European Medicines Agency: PRIME’d for access?
RG6042 (formerly named IONIS-HTTRx) is in development for Huntington’s disease. ... It’s hoped it could be a big step in treatment for the genetically-inherited and rare wasting disease.
-
Deal Watch May 2016
Teva's drug SD 809 for the treatment of Huntington's disease was part of the acquisition of Auspex at a cost of $3.5bn. ... disease late last year, Bayer announced another gene editing pact this month with ERS Genomics.
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Latest appointments
-
uniQure appoints chief executive officer
This is an exciting time for uniQure, and I am fully committed to the company's success and the execution of our core strategic goals. ... for congestive heart failure and Huntington's disease into the clinic.”.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Use of biomarkers in marketing
pathway. . When we think of biomarkers, we usually imagine the detection of genetic disorders such as Huntington’s disease and Alzheimer’s; these are prognosis biomarkers. ... A crowded market of biologics treating a chronic disease with very
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- How will the events and exhibitions industry change post-Coronavirus?
- New study identifies drugs that are safe to use in COVID-19 treatment
- Keytruda doubles five-year survival rate in NSCLC
- Novavax starts first phase 3 COVID-19 vaccine trial in the UK
- Novacyt launches diagnostic test to differentiate between COVID-19 and flu
- Relief Therapeutics seeks US emergency approval for COVID-19 drug
PMHub
Blue Latitude Health
Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...
Latest intelligence
- Switzerland: a life sciences hub
- Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
- Responding to dynamic shifts in value communications
- OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
- Doing what we can and having fun doing it: our fundraising month
- Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...
Quick links
Infographics
